CO2019006911A2 - Composiciones cannabinoides novedosas y métodos para tratar la epilepsia infantil. - Google Patents
Composiciones cannabinoides novedosas y métodos para tratar la epilepsia infantil.Info
- Publication number
- CO2019006911A2 CO2019006911A2 CONC2019/0006911A CO2019006911A CO2019006911A2 CO 2019006911 A2 CO2019006911 A2 CO 2019006911A2 CO 2019006911 A CO2019006911 A CO 2019006911A CO 2019006911 A2 CO2019006911 A2 CO 2019006911A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- childhood epilepsy
- cannabinoid compositions
- novel cannabinoid
- treat childhood
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662436861P | 2016-12-20 | 2016-12-20 | |
| PCT/IB2017/001683 WO2018115962A1 (en) | 2016-12-20 | 2017-12-20 | Novel cannabinoid compositions and methods of treating pediatric epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019006911A2 true CO2019006911A2 (es) | 2019-08-30 |
Family
ID=61028091
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0006911A CO2019006911A2 (es) | 2016-12-20 | 2019-06-27 | Composiciones cannabinoides novedosas y métodos para tratar la epilepsia infantil. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20200215022A1 (enExample) |
| EP (1) | EP3558297A1 (enExample) |
| JP (2) | JP2020514282A (enExample) |
| KR (1) | KR20190099221A (enExample) |
| AU (1) | AU2017381587A1 (enExample) |
| BR (1) | BR112019012776A2 (enExample) |
| CA (1) | CA3046320A1 (enExample) |
| CL (1) | CL2019001668A1 (enExample) |
| CO (1) | CO2019006911A2 (enExample) |
| MX (1) | MX2019007496A (enExample) |
| PE (1) | PE20200338A1 (enExample) |
| WO (1) | WO2018115962A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB201806953D0 (en) | 2018-04-27 | 2018-06-13 | Gw Res Ltd | Cannabidiol Preparations |
| IL261132A (en) * | 2018-08-13 | 2018-11-04 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof |
| GB2580653A (en) * | 2019-01-21 | 2020-07-29 | Gw Res Ltd | Use of cannabinoids in the treatment of comorbidities associated with epilepsy |
| EP3931330A4 (en) | 2019-02-25 | 2023-03-15 | Ginkgo Bioworks, Inc. | BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS |
| US11759447B1 (en) | 2019-06-26 | 2023-09-19 | RCR BioPharma | Compound and method for treating diseases and disorders |
| GB2598922A (en) * | 2020-09-18 | 2022-03-23 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| CA3217137A1 (en) | 2021-04-29 | 2022-11-03 | Christopher Adair | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| WO2023047308A1 (en) * | 2021-09-22 | 2023-03-30 | Avicanna Inc. | Methods for reducing or eliminating incidence of seizures and sudden unexpected death in epilepsy |
| JP2025512495A (ja) | 2022-04-12 | 2025-04-17 | シャッケルフォード・ファーマ・インコーポレーテッド | 発作性障害の治療 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2298284A3 (en) * | 2001-02-14 | 2013-12-18 | GW Pharma Limited | Mucoadhesive pharmaceutical formulations |
| GB2530001B (en) * | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) * | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| MX395015B (es) * | 2014-12-12 | 2025-03-24 | Ojai Energetics Pbc | Composiciones microencapsuladas de cannabinoides |
| EP3265081A4 (en) * | 2015-03-02 | 2018-11-21 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoids |
| US10555906B2 (en) * | 2016-02-11 | 2020-02-11 | Gelpell Ag | Oral solid cannabinoid formulations, methods for producing and using thereof |
-
2017
- 2017-12-20 AU AU2017381587A patent/AU2017381587A1/en not_active Abandoned
- 2017-12-20 WO PCT/IB2017/001683 patent/WO2018115962A1/en not_active Ceased
- 2017-12-20 JP JP2019534858A patent/JP2020514282A/ja active Pending
- 2017-12-20 US US16/471,407 patent/US20200215022A1/en not_active Abandoned
- 2017-12-20 BR BR112019012776-3A patent/BR112019012776A2/pt not_active IP Right Cessation
- 2017-12-20 EP EP17835701.8A patent/EP3558297A1/en not_active Withdrawn
- 2017-12-20 KR KR1020197018587A patent/KR20190099221A/ko not_active Ceased
- 2017-12-20 CA CA3046320A patent/CA3046320A1/en active Pending
- 2017-12-20 PE PE2019001299A patent/PE20200338A1/es unknown
- 2017-12-20 MX MX2019007496A patent/MX2019007496A/es unknown
-
2019
- 2019-06-17 CL CL2019001668A patent/CL2019001668A1/es unknown
- 2019-06-27 CO CONC2019/0006911A patent/CO2019006911A2/es unknown
-
2022
- 2022-10-14 JP JP2022165695A patent/JP2023001138A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019007496A (es) | 2019-10-30 |
| BR112019012776A2 (pt) | 2019-12-10 |
| JP2023001138A (ja) | 2023-01-04 |
| EP3558297A1 (en) | 2019-10-30 |
| US20200215022A1 (en) | 2020-07-09 |
| CA3046320A1 (en) | 2018-06-28 |
| PE20200338A1 (es) | 2020-02-14 |
| WO2018115962A1 (en) | 2018-06-28 |
| JP2020514282A (ja) | 2020-05-21 |
| CL2019001668A1 (es) | 2019-09-06 |
| KR20190099221A (ko) | 2019-08-26 |
| AU2017381587A1 (en) | 2019-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019006911A2 (es) | Composiciones cannabinoides novedosas y métodos para tratar la epilepsia infantil. | |
| CO2018010458A2 (es) | Composiciones y anticuerpos anti-tim-3 | |
| JO3567B1 (ar) | جزيئات جسم مضاد لـ tim-3 واستخداماتها | |
| JO3560B1 (ar) | جزيئات جسم مضاد لـ pd-1 واستخداماتها | |
| ZA201803366B (en) | Antibody molecules to april and uses thereof | |
| MX389663B (es) | Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas. | |
| BR112018012138A2 (pt) | moléculas de anticorpo para pd-1 e usos das mesmas | |
| MX2018007987A (es) | Composiciones y metodos para el tratamiento de hemoglobinopatias. | |
| JOP20150048B1 (ar) | جزيئات جسم مضاد لـ lag-3 واستخداماتها | |
| CL2015002562A1 (es) | Anticuerpos e inmunoconjugados anti-b7-h4 | |
| MX386917B (es) | Nanoportadores sintéticos tolerogénicos para reducir o prevenir anafilaxia en respuesta a un antígeno no alergénico. | |
| MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
| MX386055B (es) | Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson. | |
| MX2016004802A (es) | Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso. | |
| MX2016014227A (es) | Estabilizante para procesos de produccion de poliol polimerico. | |
| BR112019000775A2 (pt) | composições e métodos para marcar composições de hidrocarboneto com corantes não-mutagênicos | |
| TH176529A (th) | แอนทิบอดีที่จำเพาะต่อ FcRn | |
| TH180916A (th) | วิธีการคอนจูเกตแอนติบอดีจำเพาะตำแหน่ง และ องค์ประกอบ | |
| TH51216S1 (th) | อุปกรณ์คลายกล้ามเนื้อ | |
| TH180789A (th) | องค์ประกอบสำหรับการควบคุมปรับสภาพการแสดงออกของ c9orf72 | |
| TH150482S (th) | หน้าตัดโลหะ | |
| TH180268A (th) | แอนติบอดี | |
| TH180751A (th) | แอนติ-cd52 แอนติบอดี | |
| TH1501007164A (th) | ระบบซีเกลอร์-แนตตาคะตะลิสต์ที่มีประสิทธิภาพสูง, กระบวนการสำหรับการผลิตระบบคะตะลิสต์ดังกล่าวนี้, และการใช้ของสิ่งเหล่านี้ | |
| RU2012117386A (ru) | Летательный аппарат |